Samsara BioCapital LLC reduced its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 28.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 253,641 shares of the company's stock after selling 100,000 shares during the period. Arcellx comprises approximately 2.6% of Samsara BioCapital LLC's holdings, making the stock its 9th largest position. Samsara BioCapital LLC owned approximately 0.47% of Arcellx worth $19,452,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Lord Abbett & CO. LLC raised its stake in Arcellx by 2.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock valued at $74,478,000 after buying an additional 18,004 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Arcellx in the 4th quarter worth $184,000. KBC Group NV raised its holdings in Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after purchasing an additional 377 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Arcellx by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,466 shares of the company's stock valued at $879,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Legato Capital Management LLC lifted its position in Arcellx by 36.1% during the fourth quarter. Legato Capital Management LLC now owns 5,999 shares of the company's stock valued at $460,000 after purchasing an additional 1,591 shares in the last quarter. Institutional investors own 96.03% of the company's stock.
Arcellx Stock Up 0.2 %
ACLX stock opened at $64.71 on Wednesday. The business's 50-day moving average price is $64.78 and its 200-day moving average price is $74.50. The stock has a market cap of $3.56 billion, a P/E ratio of -91.14 and a beta of 0.33. Arcellx, Inc. has a twelve month low of $47.88 and a twelve month high of $107.37.
Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The firm had revenue of $15.27 million during the quarter, compared to analysts' expectations of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. On average, equities research analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Rami Elghandour sold 38,300 shares of the company's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the sale, the insider now owns 149,186 shares of the company's stock, valued at $9,252,515.72. This represents a 20.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $64.20, for a total transaction of $96,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 55,955 shares of company stock valued at $3,504,758 in the last quarter. 6.24% of the stock is currently owned by insiders.
About Arcellx
(
Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Further Reading
Want to see what other hedge funds are holding ACLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcellx, Inc. (NASDAQ:ACLX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcellx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.
While Arcellx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
